Trial Profile

A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegcetacoplan (Primary)
Indications Glomerulonephritis; IgA nephropathy; Kidney disorders; Lupus nephritis; Membranoproliferative glomerulonephritis
Focus Proof of concept; Therapeutic Use
Acronyms DISCOVERY
Sponsors Apellis Pharmaceuticals

15 Jul 2024 Status changed from active, no longer recruiting to completed.
03 Apr 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
09 Oct 2020 48-week data (n=5) presented in an Apellis Pharmaceuticals Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com